Korro Bio, Inc. (KRRO)
| Market Cap | 146.82M -15.0% |
| Revenue (ttm) | 3.84M -20.3% |
| Net Income | -113.50M |
| EPS | -11.41 |
| Shares Out | 14.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 110,058 |
| Open | 11.00 |
| Previous Close | 11.08 |
| Day's Range | 10.14 - 11.00 |
| 52-Week Range | 5.20 - 55.89 |
| Beta | 2.23 |
| Analysts | Buy |
| Price Target | 28.67 (+241.85%) |
| Earnings Date | May 7, 2026 |
About KRRO
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company’s lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe d... [Read more]
Financial Performance
In 2025, Korro Bio's revenue was $6.39 million, an increase of 181.46% compared to the previous year's $2.27 million. Losses were -$117.26 million, 40.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for KRRO stock is "Buy." The 12-month stock price target is $28.67, which is an increase of 241.85% from the latest price.
News
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to d...
Korro Bio upgraded to Buy from Hold at JonesResearch
JonesResearch upgraded Korro Bio (KRRO) to Buy from Hold with a $23 price target
JonesResearch upgrades ‘fast-follower’ Korro Bio to Buy
As previously reported, JonesResearch analyst Catherine Novack upgraded Korro Bio (KRRO) to Buy from Hold with a $23 price target after the company reported Q1 results. While both Korro’s GalNAc-conju...
Korro Bio reports Q1 EPS ($1.69), consensus ($1.98)
“The first quarter marked significant scientific progress for Korro as we continued to advance our OPERA platform and build a pipeline of differentiated RNA editing medicines,” commented Ram Aiyar, Ch...
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Hosted virtual Analyst Day showcasing lead program KRRO-121's potential to be a first-in-class transformational treatment for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic en...
Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to ...
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and...
Korro Bio files to sell 7.65M shares of common stock for holders
17:06 EDT Korro Bio (KRRO) files to sell 7.65M shares of common stock for holders
Korro Bio price target raised to $22 from $21 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Korro Bio (KRRO) to $22 from $21 and keeps an Overweight rating on the shares. The firm updated its model after Korro…
Korro Bio upgraded to Outperform from Market Perform at Raymond James
Raymond James upgraded Korro Bio (KRRO) to Outperform from Market Perform with a $23 price target The firm sees an improved outlook given the company’s pivot into hyperammonemia indications urea…
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy Advanced GalNAc-conjugated oligonucleotide for a...
Korro Bio prices 4.5M shares at $11.11 in private placement
Korro Bio (KRRO) entered into a subscription agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $85 million to the…
Korro Announces Oversubscribed $85 Million Private Placement
CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and h...
Korro to Present at the TD Cowen 46th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and hi...
Korro Bio upgraded to Buy from Hold at Clear Street
Clear Street upgraded Korro Bio (KRRO) to Buy from Hold with a price target of $18, up from $10. The firm believes new lead program, KRRO-121 for hyperammonemia, clearly addresses…
Korro Bio upgraded to Outperform from Market Perform at William Blair
William Blair upgraded Korro Bio (KRRO) to Outperform from Market Perform. The firm views the risk/reward as favorable for the OPERA Platform and KRRO-121, notes the analyst, who estimates a…
Korro Bio management to meet virtually with Cantor Fitzgerald
Virtual Meeting to be held on February 4 hosted by Cantor Fitzgerald.
Korro Bio upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Korro Bio (KRRO) to Buy from Neutral with a $20 price target The firm says KRRO-121 adds a second, “independently risk-mitigated asset as a call option.” Korro…
Korro Bio upgraded to Buy from Neutral at Chardan
Chardan upgraded Korro Bio (KRRO) to Buy from Neutral with a $15 price target following the analyst day. The company says the company has “turned the page.” It cites the…
Piper upgrades Korro to Overweight on bullish KRRO-121 view
Piper Sandler analyst Yasmeen Rahimi last night upgraded Korro Bio (KRRO) to Overweight from Neutral with a price target of $30, up from $11, following the analyst day. Piper left…
Korro Bio upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi upgraded Korro Bio (KRRO) to Overweight from Neutral with a price target of $30, up from $11.
Oppenheimer upgrades Korro Bio to Outperform as KRRO-121 offers fresh story
As previously reported, Oppenheimer upgraded Korro Bio (KRRO) to Outperform from Perform with a $22 price target Following the failure of the KRRO-110 AATD program, likely due to the LNP/delivery…
Korro Bio upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded Korro Bio (KRRO) to Outperform from Perform with a $22 price target
Korro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse upgraded Korro Bio (KRRO) to Overweight from Neutral with a $21 price target The upgrade reflects confidence in Korro’s preclinical data, clinical strategy, a...
Korro Bio price target raised to $10 from $7 at Clear Street
Clear Street raised the firm’s price target on Korro Bio (KRRO) to $10 from $7 and keeps a Hold rating on the shares following the analyst day. The company’s lead…